ClinicalTrials.Veeva

Menu

QStat in Trauma and Obstetric Hemorrhage

HemoSonics logo

HemoSonics

Status

Completed

Conditions

Blood Loss Massive
Trauma
Post Partum Hemorrhage

Treatments

Diagnostic Test: Quantra System

Study type

Observational

Funder types

Industry

Identifiers

NCT04385953
HEMCS-030

Details and patient eligibility

About

This study will evaluate the performance of the Quantra System comprised of the Quantra Hemostasis Analyzer with the QStat Cartridge in trauma patients and obstetric patients with postpartum hemorrhage.

Full description

The Quantra System is a fully integrated and automated in vitro diagnostic device which uses SEER Sonorheometry, an ultrasound-based technology, to characterize the viscoelastic properties of a whole blood sample during coagulation. The QStat Cartridge was developed to monitor hemostasis in patients that may experience a range of coagulopathies of various etiologies including fibrinolytic defects. This includes the trauma, obstetric hemorrhage and liver transplant populations. The cartridge consists of four independent channels each containing different sets of reagents, which provide four measurements performed in parallel yielding five parameters that depict the functional status of a patient's coagulation system.

This prospective, observational pilot study will evaluate the performance of the Quantra System with the QStat Cartridge as compared to comparable measures using conventional viscoelastic testing methods.

Enrollment

22 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subject is ≥ 18 years of age
  • Subject is a trauma patient experiencing major trauma (preferably requiring the highest level of team activation) with active bleeding or deemed at high risk of significant bleeding according to mechanism of injury.and is a candidate for a ROTEM test to be performed to access coagulopathy.

OR

-Subject is an obstetric patient experiencing post-partum hemorrhage based on one of the following conditions: estimated blood loss during delivery >1000 mL; placental abruption with hemorrhage of any quantity; clinically suspected DIC; pregnancy resulted in fetal demise with hemorrhage of any quantity; or is under consideration for administration of tranexamic acid for treatment of hemorrhage.

Exclusion criteria

  • Subject is younger than 18 years of age
  • Subject presents for a procedure intended to abort a pregnancy for reasons other than medical necessity
  • Subject is known to have received antifibrinolytic therapy immediately prior to presentation to trauma unit
  • Subject is currently enrolled in a distinct study that might confound the results of the proposed study
  • Subject is affected by a condition that, in the opinion of the clinical team, may pose additional risks.

Trial design

22 participants in 2 patient groups

Trauma patients
Description:
Subject experiencing major trauma
Treatment:
Diagnostic Test: Quantra System
Obstetric patients
Description:
Obstetric patient with postpartum hemorrhage
Treatment:
Diagnostic Test: Quantra System

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems